AAISG 2022 Annual Meeting

May 13, 2022 to May 15, 2022

Didactic lectures given by speakers in the therapeutic areas of: Genetic testing in allergy/immunology, COVID and allergy/immunology, Biologic medications and allergy/immunology, and more.

Accreditation   
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Allergy, Asthma and Immunology Society of Georgia (AAISG).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Practicing allergists and allied health care providers in the field of allergy and immunology.

Learning Objectives

At the conclusion of this activity learners should be able to:
1. Identify patients where genetic testing is indicated.
2. Choose the appropriate biologic therapy for allergic and immunologic diseases.
3. Manage the patient who previously has recovered from COVID infection.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

  • Ambulatory procedure centers
  • Blood banks
  • Diagnostic labs that do not sell proprietary products
  • Electronic health records companies
  • Government or military agencies
  • Group medical practices
  • Health law firms
  • Health profession membership organizations
  • Hospitals or healthcare delivery systems
  • Infusion centers
  • Insurance or managed care companies
  • Nursing homes
  • Pharmacies that do not manufacture proprietary compounds
  • Publishing or education companies
  • Rehabilitation centers
  • Schools of medicine or health science universities
  • Software or game developers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated

Gerald Lee, MD - Planner: No relevant financial relationships with ineligible companies to disclose.

Christopher Chang, MD - Speaker: Pfizer: Stock

Niraj Patel, MD - Speaker: Horizon, CSL Behring and Takeda: Speaker

Safia Nawaz, MD - Speaker: No relevant financial relationships with ineligible companies to disclose.

Sarah Biggs, MD  - Speaker: No relevant financial relationships with ineligible companies to disclose.

Bill Dolen, MD - Speaker: Aimmune: Consultant

Jennifer Shih, MD - Speaker: Pharming, ALK: Adivsory Board

Brian Vickery, MD - Speaker: Aimmune, Allergenis, Aravax, DBV, FARE, Reacta, Regeneron: Consultant

Rachel Christina Smith, MD - Speaker: No relevant financial relationships with ineligible companies to disclose.

Sofia Edwards-Salmon, MD - Speaker: No relevant financial relationships with ineligible companies to disclose.

Sarah Spriet, MD - Speaker: No relevant financial relationships with ineligible companies to disclose.

Course summary
Available credit: 
  • 7.50 AMA PRA Category 1 Credit™
  • 7.50 Attendance
Course opens: 
05/13/2022
Course expires: 
05/15/2024
Event starts: 
05/13/2022 - 7:00pm CDT
Event ends: 
05/15/2022 - 12:00pm CDT
Rating: 
0

Christopher Chang, MD

Niraj Patel, MD

Safia Nawaz, MD

Sarah Biggs, MD 

Bill Dolen, MD

Jennifer Shih, MD

Brian Vickery, MD

Christina Smith, MD

Sofia Edwards-Salmon, MD

Sarah Spriet, MD

Accreditation  

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Allergy, Asthma & Immunology Society of Georgia (AAISG).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 7.50 AMA PRA Category 1 Credit™
  • 7.50 Attendance
Please login or create an account to take this course.